Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Patients with BRCA1/2 mutations face difficult decisions on pursuing risk-reducing (and lifesaving) surgery, especially because of concerns about the safety of menopausal hormone therapy and breast cancer risk. However, observational data suggest that systemic menopausal hormone therapy does not elevate breast cancer risk among patients with pathogenic mutations with intact breasts who have undergone risk-reducing bilateral salpingo-oophorectomy (BSO) before age 45 years. Accordingly, such individuals should be considered for menopausal hormone therapy to improve quality of life and to decrease health risks associated with premature menopause. Given emerging data on the potential of estrogen-only therapy to reduce breast cancer risk, clinicians caring for women with BRCA1/2 mutations could consider offering hysterectomy along with BSO as part of risk-reducing surgery.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/AOG.0000000000005907 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Elinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause: A Phase 3 Randomized Clinical Trial.
JAMA Intern Med
September 2025
Bayer CC AG, Basel, Switzerland.
Importance: There is an unmet need for long-term, safe, effective, and hormone-free treatments for menopausal symptoms, including vasomotor symptoms (VMS) and sleep disturbances.
Objective: To evaluate the 52-week efficacy and safety of elinzanetant, a dual neurokinin-targeted therapy, for treating moderate to severe VMS associated with menopause.
Design, Setting, And Participants: OASIS-3 was a double-blind, placebo-controlled, randomized phase 3 clinical trial that was conducted at 83 sites in North America and Europe from August 27, 2021, to February 12, 2024, and included postmenopausal women aged 40 to 65 years who were seeking treatment for moderate to severe VMS (no requirement for a minimum number of VMS events per week).
The Growing Promise of Elinzanetant for Treatment of Menopausal Symptoms-Sustained Relief Without Hormones.
JAMA Intern Med
September 2025
Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Accounting for endoscopic screening in colorectal cancer risk models.
Cancer Epidemiol Biomarkers Prev
September 2025
Brigham and Women's Hospital, Boston, MA, United States.
Background: Colorectal cancer (CRC) risk models routinely adjust for endoscopic screening because of a) possible confounding with other risk factors and b) possible alteration of natural history of the disease due to adenoma detection and removal.
Methods: In this study, we defined a subject as screen-covered (SC) if a colonoscopy was performed in the past 10 years, and not screen-covered (NSC) otherwise. We created CRC risk models separately for SC and NSC subjects (HRSC, HRNSC) and then obtained a screening-coverage adjusted HR estimate (HRfull) based on a weighted average of ln(HRSC) and ln(HRNSC) with weight equal to the proportion of SC person-time in the NHS population.
Higher blood lipid levels after the transition to menopause in two forager-horticulturalist populations.
Evol Med Public Health
July 2025
Center for Evolution and Medicine, Arizona State University, Life Sciences C, 427 East Tyler Mall, Tempe, AZ 85281, USA.
Background: Reproduction affects health and longevity among females across the life course. While significant focus has been devoted to the role of menarche, menopause remains understudied. Most menopause research is conducted in industrialized populations, where the risk of cardiovascular diseases increases progressively during the menopausal transition.
View Article and Find Full Text PDFLong-Term Results of a Phase II Prospective Clinical Trial of Single-Fraction, High-Gradient Adjuvant Partial Breast Irradiation in Early-Stage, Hormone Positive Breast Cancer.
Int J Radiat Oncol Biol Phys
September 2025
Department of Radiation Oncology, Washington University School of Medicine in Saint Louis, Saint Louis, MO, USA. Electronic address:
Purpose: This study evaluates the long-term outcomes of single-fraction, high-gradient partial breast irradiation (BreaStBRT) as a post-operative treatment in patients with early-stage, hormone-positive breast cancer. It aims to assess acute and late treatment-related toxicity, cosmesis, patient-reported quality of life (QoL), and oncologic outcomes.
Materials And Methods: Single-institution, single-arm, phase II prospective trial included post-menopausal women ≥50 years old with early-stage, hormone-positive breast cancer treated with breast-conserving therapy (BCT) followed by BreaStBRT.